ANG II causes insulin resistance and induces cardiac metabolic switch and inefficiency: A critical role of PDK4

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 8, 2013, Pages

  Mori, Jun ^a   Alrob, Osama Abo ^a   Wagg, Cory S ^a   Harris, Robert A ^b   Lopaschuk, Gary D ^a   Oudit, Gavin Y ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANG II; Cardiac metabolism; Diastolic dysfunction; Insulin resistance; Sirtuin

Indexed keywords

ANGIOTENSIN II; INSULIN; PYRUVATE DEHYDROGENASE KINASE 4; SIRTUIN 3; FATTY ACID; GLUCOSE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; PYRUVATE DEHYDROGENASE (ACETYL TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE (ACETYL-TRANSFERRING) KINASE; PYRUVATE DEHYDROGENASE COMPLEX; SIRT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EX VIVO STUDY; GENE DELETION; GLUCOSE OXIDATION; HEART MUSCLE METABOLISM; HEART PERFUSION; HEART VENTRICLE HYPERTROPHY; INSULIN RESISTANCE; INSULIN RESPONSE; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CHEMICALLY INDUCED DISORDER; DIASTOLIC HEART FAILURE; DISEASE MODEL; DRUG EFFECT; ECHOCARDIOGRAPHY; ECHOGRAPHY; ENERGY METABOLISM; GENETICS; GLUCOSE TOLERANCE TEST; HEART; HEART MUSCLE; MALE; METABOLISM; MOUSE MUTANT; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FATTY ACIDS; GLUCOSE; GLUCOSE TOLERANCE TEST; HEART; HEART FAILURE, DIASTOLIC; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; OXIDATION-REDUCTION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVATE DEHYDROGENASE COMPLEX; RENIN-ANGIOTENSIN SYSTEM; SIRTUIN 3;

MLCS; MLOWN;

EID: 84878441741     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00636.2012     Document Type: Article

References (42)

1. Allard MF, Wambolt RB, Longnus SL, Grist M, Lydell CP, Parsons HL, Rodrigues B, Hall JL, Stanley WC, Bondy GP. Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am J Physiol Endocrinol Metab 279: E487-E493, 2000.
2. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295: E1323-E1332, 2008.
3. Aneja A, Tang WH, Bansilal S, Garcia MJ, Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121: 748-757, 2008.
4. Anon. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions, and congestive heart failure. The SOLVD Investigators. N Engl J Med 325: 293-302, 1991.
5. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 115: 3213-3223, 2007.
6. Cai Y, Yu SS, Chen SR, Pi RB, Gao S, Li H, Ye JT, Liu PQ. Nmnat2 protects cardiomyocytes from hypertrophy via activation of SIRT6. FEBS Lett 586: 866-874, 2012.
7. Caldiz CI, de Cingolani GE. Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. Metabolism 48: 1041-1046, 1999.
8. Connaughton S, Chowdhury F, Attia RR, Song S, Zhang Y, Elam MB, Cook GA, Park EA. Regulation of pyruvate dehydrogenase kinase isoform 4 (PDK4) gene expression by glucocorticoids and insulin. Mol Cell Endocrinol 315: 159-167, 2010.
9. Csibi A, Communi D, Muller N, Bottari SP. Angiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms. PLoS One 5: e10070, 2010.
10. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, Marcinek DJ, Dorn GW, 2nd Kang YJ, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 108: 837-846, 2011.
11. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46: 1019-1026, 2005.
12. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776, 2003.
13. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134-1146, 1999.
14. Hsieh MC, Das D, Sambandam N, Zhang MQ, Nahle Z. Regulation of the PDK4 isozyme by the Rb-E2F1 complex. J Biol Chem 283: 27410-27417, 2008.
15. Hwang YC, Jee JH, Kang M, Rhee EJ, Sung J, Lee MK. Metabolic syndrome and insulin resistance are associated with abnormal left ventricular diastolic function and structure independent of blood pressure and fasting plasma glucose level. Int J Cardiol 159: 107-111, 2012.
16. 2+-dependent but PKC-independent pathway in the cardiomyocytes. Am J Physiol Heart Circ Physiol 299: H680-H689, 2010.
17. Jaswal JS, Lund CR, Keung W, Beker DL, Rebeyka IM, Lopaschuk GD. Isoproterenol stimulates 5=-AMP-activated protein kinase and fatty acid oxidation in neonatal hearts. Am J Physiol Heart Circ Physiol 299: H1135-H1145, 2010.
18. Jeoung NH, Wu P, Joshi MA, Jaskiewicz J, Bock CB, Depaoli-Roach AA, Harris RA. Role of pyruvate dehydrogenase kinase isoenzyme 4 (PDHK4) in glucose homoeostasis during starvation. Biochem J 397: 417-425, 2006.
19. Lamb HJ, Beyerbacht HP, van der Laarse A, Stoel BC, Doornbos J, van der Wall EE, de Roos A. Diastolic dysfunction in hypertensive heart disease is associated with altered myocardial metabolism. Circulation 99: 2261-2267, 1999.
20. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90: 207-258, 2010.
21. Mori J, Basu R, McLean BA, Das SK, Zhang L, Patel VB, Wagg CS, Kassiri Z, Lopaschuk GD, Oudit GY. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5: 493-503, 2012.
22. Motley ED, Eguchi K, Gardner C, Hicks AL, Reynolds CM, Frank GD, Mifune M, Ohba M, Eguchi S. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 41: 775-780, 2003.
23. 2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103: 891-899, 2008.
24. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151, 2007.
25. Patel VB, Bodiga S, Basu R, Das SK, Wang W, Wang Z, Lo J, Grant MB, Zhong J, Kassiri Z, Oudit GY. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ Res 110: 1322-1335, 2012.
26. Paternostro G, Pagano D, Gnecchi-Ruscone T, Bonser RS, Camici PG. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 42: 246-253, 1999.
27. Pellieux C, Aasum E, Larsen TS, Montessuit C, Papageorgiou I, Pedrazzini T, Lerch R. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J Mol Cell Cardiol 41: 459-466, 2006.
28. Pellieux C, Montessuit C, Papageorgiou I, Lerch R. Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-. Cardiovasc Res 82: 341-350, 2009.
29. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
30. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 64: 2537-2565, 2004.
31. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129, 2005.
32. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4: ra46, 2011.
33. Tanno M, Kuno A, Horio Y, Miura T. Emerging beneficial roles of sirtuins in heart failure. Basic Res Cardiol 107: 273, 2012.
34. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions, and congestive heart failure. N Engl J Med 325: 293-302, 1991.
35. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Ryden L. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28: 612-616, 2005.
36. Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96: 1313-1319, 1997.
37. Tsintzas K, Chokkalingam K, Jewell K, Norton L, Macdonald IA, Constantin-Teodosiu D. Elevated free fatty acids attenuate the insulininduced suppression of PDK4 gene expression in human skeletal muscle: potential role of intramuscular long-chain acyl-coenzyme A. J Clin Endocrinol Metab 92: 3967-3972, 2007.
38. Ussher JR, Wang W, Gandhi M, Keung W, Samokhvalov V, Oka T, Wagg CS, Jaswal JS, Harris RA, Clanachan AS, Dyck JR, Lopaschuk GD. Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 94: 359-369, 2012.
39. Weber CR, Piacentino V, 3rd Houser SR, Bers DM. Dynamic regulation of sodium/calcium exchange function in human heart failure. Circulation 108: 2224-2229, 2003.
40. Wong AK, AlZadjali MA, Choy AM, Lang CC. Insulin resistance: a potential new target for therapy in patients with heart failure. Cardiovasc Ther 26: 203-213, 2008.
41. Zhang L, Ussher JR, Oka T, Cadete VJ, Wagg C, Lopaschuk GD. Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89: 148-156, 2011.
42. Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122: 717-728, 2010.